keyword
MENU ▼
Read by QxMD icon Read
search

Psychosis alzheimer

keyword
https://www.readbyqxmd.com/read/29143483/the-impact-of-mental-health-comorbidities-on-adherence-to-buprenorphine-a-claims-based-analysis
#1
Megan Litz, Douglas Leslie
BACKGROUND AND OBJECTIVES: Previous research has been inconclusive about whether opioid-dependent patients with psychiatric comorbidities have shorter treatment retention and higher relapse rates. This study aims to evaluate the impact of mental health comorbidities on adherence to buprenorphine using a large, national health insurance claims data base. METHODS: We used MarketScan® data from 2012 to 2014 to perform this analysis. Inclusion criteria included all patients with an opioid use disorder-related ICD-9 code who had been prescribed buprenorphine (n = 2947)...
November 16, 2017: American Journal on Addictions
https://www.readbyqxmd.com/read/29107450/epilepsy-as-a-network-disorder-1-what-can-we-learn-from-other-network-disorders-such-as-autistic-spectrum-disorder-and-mood-disorders
#2
REVIEW
Andres M Kanner, Helen Scharfman, Nathalie Jette, Evdokia Anagnostou, Christophe Bernard, Carol Camfield, Peter Camfield, Karen Legg, Ilan Dinstein, Peter Giacobe, Alon Friedman, Bernd Pohlmann-Eden
Epilepsy is a neurologic condition which often occurs with other neurologic and psychiatric disorders. The relation between epilepsy and these conditions is complex. Some population-based studies have identified a bidirectional relation, whereby not only patients with epilepsy are at increased risk of suffering from some of these neurologic and psychiatric disorders (migraine, stroke, dementia, autism, depression, anxiety disorders, Attention deficit hyperactivity disorder (ADHD), and psychosis), but also patients with these conditions are at increased risk of suffering from epilepsy...
October 26, 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/29073741/a-systematic-review-of-the-effectiveness-of-medical-cannabis-for-psychiatric-movement-and-neurodegenerative-disorders
#3
REVIEW
Keane Lim, Yuen Mei See, Jimmy Lee
The discovery of endocannabinoid's role within the central nervous system and its potential therapeutic benefits have brought forth rising interest in the use of cannabis for medical purposes. The present review aimed to synthesize and evaluate the available evidences on the efficacy of cannabis and its derivatives for psychiatric, neurodegenerative and movement disorders. A systematic search of randomized controlled trials of cannabis and its derivatives were conducted via databases (PubMed, Embase and the Cochrane Central Register of Controlled Trials)...
November 30, 2017: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29067350/neuropsychiatric-signs-and-symptoms-of-alzheimer-s-disease-new%C3%A2-treatment-paradigms
#4
REVIEW
Krista L Lanctôt, Joan Amatniek, Sonia Ancoli-Israel, Steven E Arnold, Clive Ballard, Jiska Cohen-Mansfield, Zahinoor Ismail, Constantine Lyketsos, David S Miller, Erik Musiek, Ricardo S Osorio, Paul B Rosenberg, Andrew Satlin, David Steffens, Pierre Tariot, Lisa J Bain, Maria C Carrillo, James A Hendrix, Heidi Jurgens, Brendon Boot
Neuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing substantial distress for both people with dementia and their caregivers, and contributing to early institutionalization. They are among the earliest signs and symptoms of neurocognitive disorders and incipient cognitive decline, yet are under-recognized and often challenging to treat. With this in mind, the Alzheimer's Association convened a Research Roundtable in May 2016, bringing together experts from academia, industry, and regulatory agencies to discuss the latest understanding of NPSs and review the development of therapeutics and biomarkers of NPSs in AD...
September 2017: Alzheimer's & Dementia: Translational Research & Clinical Interventions
https://www.readbyqxmd.com/read/29067344/determining-the-impact-of-psychosis-on-rates-of-false-positive-and-false-negative-diagnosis-in-alzheimer-s-disease
#5
Corinne E Fischer, Winnie Qian, Tom A Schweizer, Zahinoor Ismail, Eric E Smith, Colleen P Millikin, David G Munoz
INTRODUCTION: The rate of clinical misdiagnosis of Alzheimer's disease (AD) and how psychosis impacts that clinical judgment is unclear. METHODS: Using data from National Alzheimer's Coordinating Center, we compared the clinical and neuropathologic diagnosis in patients with a diagnosis of AD with autopsy and in neuropathology-confirmed AD cases (n = 961). We determined the rate of true positives, false positives, and false negatives in patients with and without psychosis...
September 2017: Alzheimer's & Dementia: Translational Research & Clinical Interventions
https://www.readbyqxmd.com/read/28990131/diagnosis-and-management-of-cognitive-and-behavioral-changes-in-dementia-with-lewy-bodies
#6
REVIEW
Babak Tousi
Proper diagnosis of dementia with Lewy bodies (DLB) in clinical practice remains suboptimal as many cases are misdiagnosed, usually as Alzheimer disease (AD) or Parkinson's disease (PD) and, in rare cases, psychosis. Therefore, it is important for patients with dementia to be thoroughly evaluated by a specialist who is familiar with current diagnostic tests and treatment options. New diagnostic criteria from the Dementia with Lewy Bodies Consortium have been developed to increase diagnostic sensitivity for DLB (Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium; McKeith et al...
October 9, 2017: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/28927477/frequency-and-subgroups-of-neuropsychiatric-symptoms-in-mild-cognitive-impairment-and-different-stages-of-dementia-in-alzheimer-s-disease
#7
N Siafarikas, G Selbaek, T Fladby, J Šaltytė Benth, E Auning, D Aarsland
BACKGROUND: Neuropsychiatric symptoms (NPS), such as depression, apathy, agitation, and psychotic symptoms are common in mild cognitive impairment (MCI) and dementia in Alzheimer's disease (AD). Subgroups of NPS have been reported. Yet the relationship of NPS and their subgroups to different stages of cognitive impairment is unclear. Most previous studies are based on small sample sizes and show conflicting results. We sought to examine the frequency of NPS and their subgroups in MCI and different stages of dementia in AD...
September 20, 2017: International Psychogeriatrics
https://www.readbyqxmd.com/read/28876969/noncognitive-behavioral-changes-associated-with-alzheimer-s-disease-implications-of-neuroimaging-findings
#8
Jeff Victoroff, Feng V Lin, Kerry L Coburn, Samuel D Shillcutt, Valerie Voon, Simon Ducharme
Alzheimer's disease (AD) is commonly associated with noncognitive behavioral changes (NCBCs). The authors systematically reviewed whether neuroimaging has helped with understanding the pathophysiology, diagnosis, or management of NCBCs associated with AD, including depression, aggression or agitation, anxiety, apathy, psychosis, and sleep disorder. The authors identified dissociable neural substrates with multimodal imaging: depression implicates the lateral and superior prefrontal cortex; apathy and agitation implicate the dorsal anterior cingulate; psychosis implicates right lateralized frontal and medial temporal areas; and anxiety implicates mesial temporal regions...
September 6, 2017: Journal of Neuropsychiatry and Clinical Neurosciences
https://www.readbyqxmd.com/read/28858444/a-population-approach-to-guide-amisulpride-dose-adjustments-in-older-patients-with-alzheimer-s-disease
#9
Suzanne Reeves, Julie Bertrand, Emma McLachlan, Fabrizia D'Antonio, Stuart Brownings, Akshay Nair, Suki Greaves, Alan Smith, Joel T Dunn, Paul Marsden, Robert Kessler, Hiroyuki Uchida, David Taylor, Robert Howard
OBJECTIVE: We have previously reported high dopamine D2/3 receptor occupancies at low amisulpride concentrations in older people with Alzheimer's disease (AD), during off-label treatment of AD-related psychosis. This post hoc analysis explored pharmacokinetic (concentration) and pharmacodynamic (prolactin, D2/3 occupancy) contributions to symptom reduction and extrapyramidal side effects (EPS) to inform AD-specific dose adjustments. METHODS: Population pharmacokinetic-pharmacodynamic models were developed by combining pharmacokinetic data from a phase 1 study in 20 healthy older people with pharmacokinetic prolactin, [¹⁸F]fallypride D2/3 receptor imaging, and clinical outcome data from 28 older patients prescribed open amisulpride (25-75 mg/d) to treat AD-related psychosis...
July 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28826872/determinants-of-behavioral-and-psychological-symptoms-of-dementia-a-scoping-review-of-the-evidence
#10
REVIEW
Ann Kolanowski, Marie Boltz, Elizabeth Galik, Laura N Gitlin, Helen C Kales, Barbara Resnick, Kimberly S Van Haitsma, Amy Knehans, Jane E Sutterlin, Justine S Sefcik, Wen Liu, Darina V Petrovsky, Lauren Massimo, Andrea Gilmore-Bykovskyi, Margaret MacAndrew, Glenna Brewster, Vycki Nalls, Ying-Ling Jao, Naomi Duffort, Danny Scerpella
BACKGROUND: Behavioral and psychological symptoms of dementia (BPSD) are prevalent in people with neurodegenerative diseases. PURPOSE: In this scoping review the Kales, Gitlin and Lykestos framework is used to answer the question: What high quality evidence exists for the patient, caregiver and environmental determinants of five specific BPSD: aggression, agitation, apathy, depression and psychosis? METHOD: An a priori review protocol was developed; 692 of 6013 articles retrieved in the search were deemed eligible for review...
September 2017: Nursing Outlook
https://www.readbyqxmd.com/read/28817967/pimavanserin-a-novel-antipsychotic-for-management-of-parkinson-s-disease-psychosis
#11
REVIEW
Yasaman Kianirad, Tanya Simuni
Parkinson's disease psychosis (PDP) may develop in up to 60% of Parkinson's patients and is associated with increased morbidity and mortality. It also correlates with depression and dementia, and can contribute to caregiver stress and burnout. Pimavanserin is the first FDA approved drug for the treatment of hallucinations and delusions associated with PDP. Areas covered: For this review, a MEDLINE literature search (via PubMed) and information provided by ACADIA Pharmaceuticals were used. This review will discuss the pathophysiology and current management of PDP...
November 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28800334/baseline-predictors-of-antipsychotic-treatment-continuation-and-response-at-week-8-in-patients-with-alzheimer-s-disease-with-psychosis-or-aggressive-symptoms-an-analysis-of-the-catie-ad-study
#12
Tomoyuki Nagata, Shinichiro Nakajima, Shunichiro Shinagawa, Eric Plitman, Kazuhiko Nakayama, Ariel Graff-Guerrero, Masaru Mimura
BACKGROUND/OBJECTIVE: The aim of the present study was to investigate predictors of atypical antipsychotic (AAP) treatment continuation and response by week 8 in patients with Alzheimer's disease (AD) who have psychotic/aggressive symptoms using the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) dataset. METHODS: Clinical data was utilized from 421 AD outpatients with psychotic/aggressive symptoms who needed interventional treatment...
2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28762173/methylene-blue-and-its-analogues-as-antidepressant-compounds
#13
REVIEW
Anzelle Delport, Brian H Harvey, Anél Petzer, Jacobus P Petzer
Methylene Blue (MB) is considered to have diverse medical applications and is a well-described treatment for methemoglobinemias and ifosfamide-induced encephalopathy. In recent years the focus has shifted to MB as an antimalarial agent and as a potential treatment for neurodegenerative disorders such as Alzheimer's disease. Of interest are reports that MB possesses antidepressant and anxiolytic activity in pre-clinical models and has shown promise in clinical trials for schizophrenia and bipolar disorder. MB is a noteworthy inhibitor of monoamine oxidase A (MAO-A), which is a well-established target for antidepressant action...
July 31, 2017: Metabolic Brain Disease
https://www.readbyqxmd.com/read/28754095/comparison-of-neuropsychiatric-symptoms-and-diffusion-tensor-imaging-correlates-among-patients-with-subcortical-ischemic-vascular-disease-and-alzheimer-s-disease
#14
Min-Chien Tu, Wen-Hui Huang, Yen-Hsuan Hsu, Chung-Ping Lo, Jie Fu Deng, Ching-Feng Huang
BACKGROUND: The causes of behavioral and psychological symptoms of dementia (BPSD) vary according to the dementia subtype and associated neuropathology. The present study aimed to (i) compare BPSD between patients with subcortical ischemic vascular disease (SIVD) and Alzheimer's disease (AD) across stages, and (ii) explore the associations with diffusion tensor imaging (DTI) in the corpus callosum (CC) and other major fibers. METHODS: Twenty-four patients with SIVD and 32 with AD were recruited...
July 28, 2017: BMC Neurology
https://www.readbyqxmd.com/read/28741694/reduced-parahippocampal-volume-and-psychosis-symptoms-in-alzheimer-s-disease
#15
Emma McLachlan, Jennifer Bousfield, Robert Howard, Suzanne Reeves
OBJECTIVE: Establishing structural imaging correlates of psychosis symptoms in Alzheimer's disease (AD) could localise pathology and target symptomatic treatment. This study investigated whether psychosis symptoms are associated with visuoperceptual or frontal networks, and whether regional brain volume differences could be linked with the paranoid (persecutory delusions) or misidentification (misidentification phenomena and/or hallucinations) subtypes. METHODS: A total of 104 patients with probable AD (AddNeuroMed; 47 psychotic, 57 non-psychotic), followed up for at least one year with structural MRI at baseline...
July 25, 2017: International Journal of Geriatric Psychiatry
https://www.readbyqxmd.com/read/28732807/pharmacology-and-toxicology-of-%C3%AE-and-%C3%AE-asarone-a-review-of-preclinical-evidence
#16
REVIEW
Ranjithkumar Chellian, Vijayapandi Pandy, Zahurin Mohamed
BACKGROUND: Asarone is one of the most researched phytochemicals and is mainly present in the Acorus species and Guatteria gaumeri Greenman. In preclinical studies, both α- and β-asarone have been reported to have numerous pharmacological activities and at the same time, many studies have also revealed the toxicity of α- and β-asarone. PURPOSE: The purpose of this comprehensive review is to compile and analyze the information related to the pharmacokinetic, pharmacological, and toxicological studies reported on α- and β-asarone using preclinical in vitro and in vivo models...
August 15, 2017: Phytomedicine: International Journal of Phytotherapy and Phytopharmacology
https://www.readbyqxmd.com/read/28689190/intermediate-c9orf72-alleles-in-neurological-disorders-does-size-really-matter
#17
Adeline S L Ng, Eng-King Tan
C9orf72 repeat expansions is a major cause of familial frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) worldwide. Sizes of <20 hexanucleotide repeats are observed in controls, while up to thousands associate with disease. Intermediate C9orf72 repeat lengths, however, remain uncertain. We systematically reviewed the role of intermediate C9orf72 alleles in C9orf72-related neurological disorders. We identified 49 studies with adequate available data on normal or intermediate C9orf72 repeat length, involving subjects with FTD, ALS, Parkinson's disease (PD), atypical parkinsonism, Alzheimer's disease (AD) and other aetiologies...
September 2017: Journal of Medical Genetics
https://www.readbyqxmd.com/read/28643852/therapeutic-d2-3-receptor-occupancies-and-response-with-low-amisulpride-blood-concentrations-in-very-late-onset-schizophrenia-like-psychosis-vloslp
#18
Suzanne Reeves, Kate Eggleston, Elizabeth Cort, Emma McLachlan, Stuart Brownings, Akshay Nair, Suki Greaves, Alan Smith, Joel Dunn, Paul Marsden, Robert Kessler, David Taylor, Julie Bertrand, Robert Howard
OBJECTIVE: Antipsychotic drug sensitivity in very late-onset schizophrenia-like psychosis (VLOSLP) is well documented, but poorly understood. This study aimed to investigate blood drug concentration, D2/3 receptor occupancy and outcome in VLOSLP during open amisulpride prescribing, and compare this with Alzheimer's disease (AD). METHODS: Blood drug concentration, prolactin, symptoms and extrapyramidal side-effects (EPS) were serially assessed during dose titration...
June 23, 2017: International Journal of Geriatric Psychiatry
https://www.readbyqxmd.com/read/28554324/multi-target-directed-ligands-affecting-serotonergic-neurotransmission-for-alzheimer-s-disease-therapy-advances-in-chemical-and-biological-research
#19
Agnieszka Jankowska, Anna Wesołowska, Maciej Pawłowski, Grażyna Chłoń-Rzepa
Alzheimer's disease (AD) is an age-related neurodegenerative disorder characterized by a progressive cognitive impairments and chronic inflammation that affects over 30 million people all over the world. Most of Alzheimer's patients also suffer from psychosis, aggression, agitation, depression, anxiety, and many other behavioral and psychological symptoms of dementia. Unfortunately, currently available anti-AD drugs provide modest symptomatic relief, and do not reverse the neurodegeneration. Consequently, the average life expectancy after diagnosis is between six to ten years...
May 29, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28532646/the-novel-psen1-m84v-mutation-associated-to-frontal-dysexecutive-syndrome-spastic-paraparesis-and-cerebellar-atrophy-in-a-dominant-alzheimer-s-disease-family
#20
Maura Gallo, Francesca Frangipane, Chiara Cupidi, Matteo De Bartolo, Sabina Turone, Camilla Ferrari, Benedetta Nacmias, Giuliana Grimaldi, Valentina Laganà, Rosanna Colao, Livia Bernardi, Maria Anfossi, Maria Elena Conidi, Franca Vasso, Sabrina Anna Maria Curcio, Maria Mirabelli, Nicoletta Smirne, Giusi Torchia, Maria Gabriella Muraca, Gianfranco Puccio, Raffaele Di Lorenzo, Maristella Piccininni, Andrea Tedde, Raffaele Giovanni Maletta, Sandro Sorbi, Amalia Cecilia Bruni
We identified the novel PSEN1 pathogenic mutation M84V in 3 patients belonging to a large kindred affected by autosomal dominant Alzheimer's disease (AD). The clinical phenotype was characterized by early onset dementia in 14 affected subjects over 3 generations. Detailed clinical, imaging and genetic assessment was performed. We highlighted the presence of unusual symptoms such as frontal executive syndrome, psychosis and spastic paraparesis in these patients. Spastic paraparesis has been reported in other PSEN1 mutations in adjacent codons, suggesting that the position of the genetic defect may affect the clinical expression, although this phenotype can occur in mutations throughout the whole PSEN1 gene...
April 27, 2017: Neurobiology of Aging
keyword
keyword
71288
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"